Long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52‐week postmarketing clinical study ( <scp>TWINKLE</scp> )
This study confirmed the favorable safety profile and sustained glycemic efficacy of imeglimin in Japanese individuals with T2D and CKD stages G3b-5, supporting its use with dose adjustment in this population.
Authors
- Eitaro Nakashima
- Kei Watabe
- Masayuki Kashima (ORCID: https://orcid.org/0009-0003-0627-351X)
- Katsuhiko Hagi (ORCID: https://orcid.org/0000-0003-1389-1474)
- Noriko Nunami
- Takeshi Osonoi (ORCID: https://orcid.org/0000-0002-5410-9277)
- Tetsuya Babazono (ORCID: https://orcid.org/0000-0001-8545-3604)
- Yukiko Onishi (ORCID: https://orcid.org/0000-0003-1180-5982)
- Daiji Kawanami (ORCID: https://orcid.org/0000-0002-8926-4701)
- Hideki Okamoto (ORCID: https://orcid.org/0000-0002-7551-8694)
- Shinya Nakamoto
Institutions
- Sumitomo Chemical (Japan) (JP)
- Sumitomo Dainippon Pharma (Japan) (JP)
- Fukuoka University (JP)
- The Institute of Medical Science, Asahi Life Foundation (JP)
- Chubu Rosai Hospital (JP)
- Mito Saiseikai General Hospital (JP)
- Japanese Red Cross Kumamoto Hospital (JP)
- Meitetsu Hospital (JP)
- The Nakamura Hajime Eastern Institute (JP)
- Tokyo Women's Medical University (JP)
- Kinan Hospital (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1111/jdi.70135
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nihon University
- Dainippon Sumitomo Pharma
- Tokyo Women's Medical University